Still, some early clinical findings hint at potential uses in more specific contexts: Perioperative brain protection: A randomized controlled trial involving 155 liver surgery patients found that ALA reduced oxidative brain injury from anesthesia (sevoflurane) and improved cognitive recovery scores after surgery.31 Neurodegenerative conditions: In a small trial, ALA appeared to slow brain atrophy in patients with secondary progressive multiple sclerosis over a two-year period.32 While promising, this outcome still needs further confirmation
The early indicators of the GLP-1 weight loss era Predictably, these drugs are attracting huge industry and media attention
Its a powerful tool for research, and like any powerful tool, it demands respect, precision, and a deep understanding of its function
While GLP-1 jabs have been shown in randomised controlled trials lead to weight loss of 15 to 20%, around half of all patients discontinue their use within the first year, with three-quarters stopping after two years
The answer is yes, they can be an option for many hypothyroid patients but several important nuances are easy to miss